In a significant boost to the biotech industry, SanegeneBio, a Chinese clinical-stage biotech company backed by tech giant Tencent, has successfully raised over $110 million in its Series B financing round.
This landmark funding, announced on December 9, 2025, underscores growing investor confidence in SanegeneBio’s innovative approach to RNA-based therapeutics.
SanegeneBio’s Mission to Transform Healthcare
Headquartered in Suzhou with additional operations in Boston and Shanghai, SanegeneBio is focused on developing cutting-edge RNAi (RNA interference) medicines targeting cardiometabolic diseases.
The company’s proprietary technology aims to address unmet medical needs by precisely targeting tissues, a challenge that has long hindered the efficacy of RNA-based treatments.
A Strategic Partnership with Eli Lilly
Adding to its momentum, SanegeneBio recently entered a $1.2 billion research pact with pharmaceutical giant Eli Lilly to advance cardiometabolic RNA therapies, as reported by Fierce Biotech.
This collaboration highlights the potential global impact of SanegeneBio’s research and its ability to attract major industry players.
Historical Growth and Investor Support
Since its earlier funding rounds, including an extended Series A co-led by Tencent in 2023, SanegeneBio has consistently demonstrated its capacity to scale, as noted by DealStreetAsia.
The latest Series B funding will likely fuel clinical trials and expand research capabilities, positioning the company as a leader in China’s booming biotech sector.
Future Prospects and Industry Impact
Looking ahead, SanegeneBio aims to accelerate the development of its pipeline, potentially bringing life-changing treatments to market within the next few years.
The success of this funding round could inspire further investments in RNA therapeutics, a field poised to redefine modern medicine.
With China emerging as a global hub for biotech innovation, SanegeneBio’s achievements may pave the way for other startups to secure significant backing.
As the company continues to grow, the industry watches closely, anticipating how its advancements will shape the future of healthcare solutions.
Alfred Lee
